Back to mobile site

Form 6-K NYMOX PHARMACEUTICAL For: Mar 27

March 27, 2026 4:37 PM EDT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of March, 2026

 

Commission File Number: 001-12033

 

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

 

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

 

On March 27, 2026, the Company issued a press release announcing upcoming changes to the Board of Directors, share purchase by the CEO, and a note of remembrance of the Company's late distinguished Co-Chairman James G. Robinson. This press release is furnished as Exhibit 99.1. The press release furnished as Exhibit 99.1 to this report on Form 6-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

 

 

2

 

 

EXHIBIT INDEX

 

Exhibit No.

Description

99.1

Press Release of Nymox Pharmaceutical Corporation, dated March 27, 2026

 

 

3

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 27, 2026

 

NYMOX PHARMACEUTICAL CORPORATION

 

 

 

 

By:

/s/ Paul Averback

 

Name:

Paul Averback

 

Title:

President and Chief Executive Officer

 

 

4

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

PRESS RELEASE



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings